4.09
+7.07%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vanda Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Vanda Pharmaceuticals is based in Washington, Washington, DC and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VNDA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $216.1m and a net loss of $220.5m. At that date it held total assets of $488.9m and shareholders' equity of $327.2m.
Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
We strive to advance novel approaches to bring important new medicines to market through responsible innovation. We are committed to the use of technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and the commercial positioning of our products.
We were incorporated in 2002 and commenced operations in 2003. We are headquartered in Washington, D.C.
In May 2009, the FDA granted U.S. marketing approval of Fanapt® for the acute treatment of schizophrenia in adults. At that time, we had certain worldwide exclusive rights relating to Fanapt®, which we obtained pursuant to a sublicense agreement entered into with Novartis Pharma AG (Novartis) in June 2004. In October 2009, we amended and restated our sublicense agreement with Novartis pursuant to which Novartis retained exclusive commercialization rights to all formulations of Fanapt® in the U.S. and Canada. In January 2010, Novartis launched Fanapt® in the U.S. On December 31, 2014, Novartis transferred all the U.S. and Canadian commercial rights to the Fanapt® franchise to us as part of a settlement agreement. Additionally, our distribution partners launched Fanapt® in Israel in 2014. In May 2016, the FDA approved a supplemental New Drug Application (sNDA) for Fanapt® for the maintenance treatment of schizophrenia in adults.
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Apr 2006
- Employees
- 533
- Website
- vandapharma.com ↗
- Head office
- 2200 PENNSYLVANIA AVE NW, WASHINGTON, DC, 20037
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Mihael PolymeropoulosChairman of the Board, President, Chief Executive Officer, since 2003$3.9m
- Mr. Kevin MoranChief Financial Officer, Senior Vice President, Treasurer$1.4m
- Mr. Joakim WijkstromSenior Vice President, Chief Marketing Officer$1.1m
- Mr. Timothy WilliamsSenior Vice President, General Counsel, Secretary$1.5m
- Mr. Gunther BirznieksSenior Vice President - Business Development$1.4m
- Mr. Richard DuganLead Independent Director$336,864
- Ms. Phaedra ChrousosIndependent Director$302,908
- Dr. Tage HonoreIndependent Director$285,033
- Dr. Stephen MitchellIndependent Director$282,496
- Ms. Anne WardIndependent Director$306,864
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 51
- Environment
- 56
- Social
- 47
- Governance
- 50
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vanda Pharmaceuticals Inc has a strong portfolio of innovative and patented drugs, offering a competitive advantage in the pharmaceutical industry. The company's research and development capabilities are robust, allowing it to continuously develop and bring new drugs to market. Vanda Pharmaceuticals also has a dedicated and skilled workforce, contributing to its overall strength.
Weaknesses
- One of the weaknesses of Vanda Pharmaceuticals Inc is its dependence on limited drug offerings. The company's revenue streams heavily rely on a few key drugs, making it vulnerable to competition and potential market fluctuations. Another weakness is the high costs associated with drug development and regulatory processes.
Opportunities
- Vanda Pharmaceuticals Inc has several opportunities for growth and expansion. The increasing prevalence of certain medical conditions, for which the company offers effective drug treatments, presents a favorable market environment. Vanda Pharmaceuticals can also capitalize on strategic partnerships and collaborations to access new markets and enhance its product offerings.
Threats
- Vanda Pharmaceuticals Inc faces various threats that could impact its performance and market position. One significant threat is the potential loss of patents and exclusivity rights, which would expose the company's drugs to generic competition. Additionally, changes in government regulations and policies, as well as adverse events related to drug safety, pose threats to Vanda Pharmaceuticals' operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.